COMP <GO>
LII vs TMO // FORWARD P/E MULTIPLE
Lennox International Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: LII 9
— TMO 6
▲ FORWARD P/E MULTIPLE LEADER: LII
LAST: $344.08 (-1.16%) • MKT CAP: $11.91B
forward-pe
13.8x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
forward-pe
36.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LII VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LII | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 33.40% | 41.00% | -7.60 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 34.90% | 9.30% | +25.60 | LII | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.5x | 30.4x | -18.90 | LII | /valuation <GO> |
| Free Cash Flow Yield | 5.36% | 2.40% | +2.96 | LII | /fcf-yield <GO> |
| Operating Margin | 20.00% | 17.40% | +2.60 | LII | /operating-margins <GO> |
| Net Profit Margin | 15.50% | 15.10% | +0.40 | LII | /net-margins <GO> |
| Revenue Growth (YoY) | -2.70% | 3.90% | -6.60 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.45% | 0.24% | +1.21 | LII | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.45 | 4.50 | +1.95 | LII | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.70% | +0.10 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.3 | 59.1 | -17.88 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.94 | +0.02 | LII | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 13.8x | 36.3x | -22.50 | LII | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.91B | $262.22B | -$250.31B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LII REV | TMO REV | LII GROSS % | TMO GROSS % | LII FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.20B | $44.56B | 33.4% | 44.0% | $638.8M | $6.29B |
| FY 2024 | $5.34B | $42.88B | 33.3% | 44.0% | $782.1M | $7.27B |
| FY 2023 | $4.98B | $42.86B | 44.0% | 44.0% | $512.0M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LII // BETA 0.96
TMO // BETA 0.94